KR20060017791A - 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트 - Google Patents
호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트 Download PDFInfo
- Publication number
- KR20060017791A KR20060017791A KR1020057021923A KR20057021923A KR20060017791A KR 20060017791 A KR20060017791 A KR 20060017791A KR 1020057021923 A KR1020057021923 A KR 1020057021923A KR 20057021923 A KR20057021923 A KR 20057021923A KR 20060017791 A KR20060017791 A KR 20060017791A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- phenyl
- ester
- pyridin
- carbamic acid
- Prior art date
Links
- 0 CC1(*)CC(OC(N(C*)C2=CC=CC(C)(*)C=C2)=O)=NC=C(*)C1 Chemical compound CC1(*)CC(OC(N(C*)C2=CC=CC(C)(*)C=C2)=O)=NC=C(*)C1 0.000 description 6
- APRSVNSCJPAOFV-UHFFFAOYSA-N CCCN(C(CC(C)(C)C1)=O)C1=O Chemical compound CCCN(C(CC(C)(C)C1)=O)C1=O APRSVNSCJPAOFV-UHFFFAOYSA-N 0.000 description 1
- QDHJXTKDANTJDA-UHFFFAOYSA-N CCSC1=[I]C=CC=C1 Chemical compound CCSC1=[I]C=CC=C1 QDHJXTKDANTJDA-UHFFFAOYSA-N 0.000 description 1
- KTHHGWBSZFCEPT-UHFFFAOYSA-N CCSc1ccncc1 Chemical compound CCSc1ccncc1 KTHHGWBSZFCEPT-UHFFFAOYSA-N 0.000 description 1
- DRVRALGHBQQJAK-UHFFFAOYSA-N CCc(cc1)ncc1Cl Chemical compound CCc(cc1)ncc1Cl DRVRALGHBQQJAK-UHFFFAOYSA-N 0.000 description 1
- FTKZKUSQFCXEEL-UHFFFAOYSA-N CCc1c(C)cccn1 Chemical compound CCc1c(C)cccn1 FTKZKUSQFCXEEL-UHFFFAOYSA-N 0.000 description 1
- COHDGTRFTKHYSJ-UHFFFAOYSA-N CCc1ccc(C)cn1 Chemical compound CCc1ccc(C)cn1 COHDGTRFTKHYSJ-UHFFFAOYSA-N 0.000 description 1
- SFSXNVBMAODLGN-UHFFFAOYSA-N CCc1nc(C)ccc1 Chemical compound CCc1nc(C)ccc1 SFSXNVBMAODLGN-UHFFFAOYSA-N 0.000 description 1
- SOHMZGMHXUQHGE-UHFFFAOYSA-N Cc(cc1)cnc1O Chemical compound Cc(cc1)cnc1O SOHMZGMHXUQHGE-UHFFFAOYSA-N 0.000 description 1
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N Cc1cc(C)ncc1 Chemical compound Cc1cc(C)ncc1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N Cc1cccc(C)n1 Chemical compound Cc1cccc(C)n1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N Cc1cccnc1C Chemical compound Cc1cccnc1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N Cc1cnc(C)cc1 Chemical compound Cc1cnc(C)cc1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- ZBCOTWQYKCHKQK-UHFFFAOYSA-N Cc1ncc(C(F)(F)F)cc1 Chemical compound Cc1ncc(C(F)(F)F)cc1 ZBCOTWQYKCHKQK-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ncccc1 Chemical compound Cc1ncccc1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BYRJSCNPUHYZQE-UHFFFAOYSA-N Oc1ccc(C(F)(F)F)cn1 Chemical compound Oc1ccc(C(F)(F)F)cn1 BYRJSCNPUHYZQE-UHFFFAOYSA-N 0.000 description 1
- SZFUWUOHDRMCKD-UHFFFAOYSA-M [O-]c(cc1)ncc1Cl Chemical compound [O-]c(cc1)ncc1Cl SZFUWUOHDRMCKD-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300879 | 2003-06-12 | ||
DKPA200300879 | 2003-06-12 | ||
US47852603P | 2003-06-13 | 2003-06-13 | |
US60/478,526 | 2003-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20060017791A true KR20060017791A (ko) | 2006-02-27 |
Family
ID=33553690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057021923A KR20060017791A (ko) | 2003-06-12 | 2004-06-08 | 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1636205A1 (no) |
JP (1) | JP2006527210A (no) |
KR (1) | KR20060017791A (no) |
AU (1) | AU2004247319A1 (no) |
BR (1) | BRPI0411255A (no) |
CA (1) | CA2526204A1 (no) |
MX (1) | MXPA05013224A (no) |
NO (1) | NO20060168L (no) |
RU (1) | RU2337908C2 (no) |
WO (1) | WO2004111031A1 (no) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4943837B2 (ja) | 2003-04-03 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良インヒビター |
US20090018092A1 (en) | 2004-03-16 | 2009-01-15 | The Regents Of The University Of California | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
JP2008530173A (ja) * | 2005-02-15 | 2008-08-07 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼ阻害剤としてのメチルフェニルカルバミン酸5−(4−イソブチル−2,6−ジオキソピペラジン−1−イル)ピリジン−2−イルエステルおよび塩 |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
CA2620878A1 (en) * | 2005-08-29 | 2007-04-05 | Gerard M. Housey | Theramutein modulators |
AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
AU2013205325B2 (en) * | 2006-03-27 | 2016-03-24 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
AU2016201061B2 (en) * | 2006-03-27 | 2017-03-02 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
DK2656841T3 (en) | 2006-03-27 | 2016-12-05 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
RU2449993C2 (ru) | 2006-03-29 | 2012-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Диарилтиогидантоиновые соединения |
BRPI0717106A2 (pt) * | 2006-09-21 | 2013-10-08 | Piramal Life Sciences Ltd | Compostos para o tratamento de distúrbios metabólicos |
FR2912404B1 (fr) | 2007-02-09 | 2009-04-10 | Sanofi Aventis Sa | Derives d'azabicycloalkane,leur preparation et leur application en therapeutique. |
CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
JP5634506B2 (ja) | 2009-05-12 | 2014-12-03 | ジャンセン ファーマシューティカルズ, インコーポレイテッド | 1,2,3−トリアゾロ[4,3−a]ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
WO2011103202A2 (en) | 2010-02-16 | 2011-08-25 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
ES2963218T3 (es) | 2011-12-28 | 2024-03-25 | Global Blood Therapeutics Inc | Productos intermedios para obtener compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
KR20220025231A (ko) | 2012-09-26 | 2022-03-03 | 아라곤 파마슈티컬스, 인코포레이티드 | 비전이성 거세 저항성 전립선암 치료용 항안드로겐 |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MX2015014336A (es) * | 2013-04-12 | 2016-06-07 | Obschestvo S Ogranichennoi Otveststvennostiyu Pharmentpr | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
CA2916564C (en) | 2014-02-07 | 2023-02-28 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
MX2021005559A (es) | 2018-11-14 | 2021-09-10 | Altavant Sciences Gmbh | Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización. |
MD3880654T2 (ro) | 2018-11-19 | 2022-05-31 | Global Blood Therapeutics Inc | Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10010968A1 (de) * | 2000-03-07 | 2001-09-13 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
AU2001260076A1 (en) * | 2000-05-15 | 2001-11-26 | Novo-Nordisk A/S | Compounds for treating disorders where a decreased level of plasma ffa is desired |
US7067517B2 (en) * | 2001-12-14 | 2006-06-27 | Nero Nordisk A/S | Use of compounds for decreasing activity of hormone-sensitive lipase |
-
2004
- 2004-06-08 EP EP04736303A patent/EP1636205A1/en not_active Withdrawn
- 2004-06-08 AU AU2004247319A patent/AU2004247319A1/en not_active Abandoned
- 2004-06-08 KR KR1020057021923A patent/KR20060017791A/ko not_active Application Discontinuation
- 2004-06-08 CA CA002526204A patent/CA2526204A1/en not_active Abandoned
- 2004-06-08 JP JP2006515703A patent/JP2006527210A/ja not_active Withdrawn
- 2004-06-08 MX MXPA05013224A patent/MXPA05013224A/es not_active Application Discontinuation
- 2004-06-08 BR BRPI0411255-5A patent/BRPI0411255A/pt not_active IP Right Cessation
- 2004-06-08 RU RU2005137716/04A patent/RU2337908C2/ru not_active IP Right Cessation
- 2004-06-08 WO PCT/DK2004/000391 patent/WO2004111031A1/en active Application Filing
-
2006
- 2006-01-12 NO NO20060168A patent/NO20060168L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2005137716A (ru) | 2006-05-27 |
CA2526204A1 (en) | 2004-12-23 |
MXPA05013224A (es) | 2006-03-09 |
NO20060168L (no) | 2006-03-10 |
WO2004111031A1 (en) | 2004-12-23 |
BRPI0411255A (pt) | 2006-08-01 |
AU2004247319A1 (en) | 2004-12-23 |
JP2006527210A (ja) | 2006-11-30 |
EP1636205A1 (en) | 2006-03-22 |
RU2337908C2 (ru) | 2008-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20060017791A (ko) | 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트 | |
US7279470B2 (en) | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | |
US6380218B1 (en) | Nicotinamide derivatives | |
TWI422579B (zh) | 新化合物 | |
JP2006527212A (ja) | ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート | |
US20060160851A1 (en) | Substituted piperidine carbamates | |
EP2514748B1 (en) | 2,4-diaminoquinazolines for spinal muscular atrophy | |
US20060160819A1 (en) | Substitued piperazine carbamates | |
US20060160865A1 (en) | Pyridinyl carbamates | |
US20060148799A1 (en) | Substituted p-phenyl carbamates | |
JP2006527214A (ja) | パラ置換されたフェニルカルバメート | |
RU2317981C2 (ru) | Соединения и их применение для снижения активности гормон-чувствительной липазы | |
US20060148860A1 (en) | Substituted p-phenyl carbamates | |
JP2006527215A (ja) | パラ置換されたフェニルカルバメート | |
JP2008530173A (ja) | ホルモン感受性リパーゼ阻害剤としてのメチルフェニルカルバミン酸5−(4−イソブチル−2,6−ジオキソピペラジン−1−イル)ピリジン−2−イルエステルおよび塩 | |
EP1452522A2 (en) | Novel compounds and compositions as protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |